Vaxcyte annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
Vaxcyte Depreciation & Amortization Growth & History (PCVX)
Vaxcyte's depreciation and amortization was $16.4M for fiscal 2025.
View full Vaxcyte company overviewVaxcyte annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16.4M | $9.4M | +134.13% |
| 2024 | 2024-12-31 | $7.0M | $3.8M | +121.89% |
| 2023 | 2023-12-31 | $3.2M | $322,000 | +11.36% |
| 2022 | 2022-12-31 | $2.8M | $1.0M | +57.44% |
| 2021 | 2021-12-31 | $1.8M | $395,000 | +28.11% |
| 2020 | 2020-12-31 | $1.4M | $173,000 | +14.04% |
| 2019 | 2019-12-31 | $1.2M | $195,000 | +18.80% |
| 2018 | 2018-12-31 | $1.0M | — | — |
Vaxcyte quarterly depreciation and amortization
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.0M | $123,000 | +4.27% |
| Q1 2026 | 2026-03-31 | $2.9M | −$9,000 | −0.30% |
| Q4 2025 | 2025-12-31 | $9.8M | — | — |
| Q3 2025 | 2025-09-30 | $3.1M | $1.3M | +70.22% |
| Q2 2025 | 2025-06-30 | $2.9M | $1.5M | +105.64% |
| Q1 2025 | 2025-03-31 | $3.0M | $2.0M | +195.90% |
| Q3 2024 | 2024-09-30 | $1.8M | $1.0M | +125.00% |
| Q2 2024 | 2024-06-30 | $1.4M | $600,000 | +75.00% |
| Q1 2024 | 2024-03-31 | $999,000 | $287,000 | +40.31% |
| Q3 2023 | 2023-09-30 | $800,000 | $100,000 | +14.29% |
| Q2 2023 | 2023-06-30 | $800,000 | $200,000 | +33.33% |
| Q1 2023 | 2023-03-31 | $712,000 | $130,000 | +22.34% |
| Q3 2022 | 2022-09-30 | $700,000 | $200,000 | +40.00% |
| Q2 2022 | 2022-06-30 | $600,000 | $100,000 | +20.00% |
| Q1 2022 | 2022-03-31 | $582,000 | $235,000 | +67.72% |
| Q3 2021 | 2021-09-30 | $500,000 | $200,000 | +66.67% |
| Q2 2021 | 2021-06-30 | $500,000 | $100,000 | +25.00% |
| Q1 2021 | 2021-03-31 | $347,000 | −$37,000 | −9.64% |
| Q3 2020 | 2020-09-30 | $300,000 | $0 | 0.00% |
| Q2 2020 | 2020-06-30 | $400,000 | $100,000 | +33.33% |
| Q1 2020 | 2020-03-31 | $384,000 | — | — |
| Q3 2019 | 2019-09-30 | $300,000 | — | — |
| Q2 2019 | 2019-06-30 | $300,000 | — | — |
Vaxcyte depreciation and amortization trends
Over the last five fiscal years, Vaxcyte's depreciation and amortization increased from $1.4M to $16.4M, a change of $15.0M. The latest reported quarter, Q2 2026, shows $3.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vaxcyte source filings ↗